Dystonia
- PMID: 11096754
- DOI: 10.1007/s11940-000-0009-y
Dystonia
Abstract
Therapy for most people with dystonia is symptomatic, directed at lessening the intensity of the dystonic contractions. For a small minority of patients (eg, those with dopa-responsive dystonia, Wilson's disease, or psychogenic dystonia), specific therapy directed at one of the many causes of dystonia is available. Before initiating treatment, clinicians need to decide if a patient has a form of dystonia amenable to such therapy. The most sensitive and least costly method to diagnose DRD is a therapeutic trial of levodopa. It is, therefore, recommended to treat all those with dystonia beginning in childhood or adolescence with low-dose levodopa. For patients with generalized or segmental signs who do not respond to levodopa, other oral medications, including anticholinergics, baclofen, and benzodiazepines, may provide mild to moderate relief; these medications are often given in combinations. For those with focal dystonia, most having adult-onset disease, botulinum toxin A injections often effectively control contractions. The injections produce transient weakness and need to be repeated, generally every 3 to 5 months. There is growing renewed interest in surgical treatment. Peripheral denervating procedures may be helpful for patients with torticollis who do not obtain adequate benefit with botulinum toxin A. The central procedures of pallidotomy and pallidal stimulation are under study; their place in the treatment of the many dystonia subtypes (eg, limb vs axial, generalized vs focal, primary vs secondary) still needs to be established. There are very few studies evaluating physical and psychological therapies or the impact of diet or lifestyle in dystonia. Most clinicians consider physical therapy, including massage, a potential adjunct to medical therapy, and psychological support and stress reduction may help individuals cope with this chronic and frequently disabling condition.
Similar articles
-
Torsion Dystonia in Children.Curr Treat Options Neurol. 2003 Jul;5(4):291-297. doi: 10.1007/s11940-003-0035-7. Curr Treat Options Neurol. 2003. PMID: 12791196
-
[Medical aspects of the medical treatment in dystonia].Bull Acad Natl Med. 2011 Apr-May;195(4-5):935-50. Bull Acad Natl Med. 2011. PMID: 22375361 Review. French.
-
Treatment of dystonia.Lancet Neurol. 2006 Oct;5(10):864-72. doi: 10.1016/S1474-4422(06)70574-9. Lancet Neurol. 2006. PMID: 16987733 Review.
-
Update on current and emerging therapies for dystonia.Neurodegener Dis Manag. 2019 Jun;9(3):135-147. doi: 10.2217/nmt-2018-0047. Epub 2019 May 22. Neurodegener Dis Manag. 2019. PMID: 31117876 Review.
-
Chapter 33: the history of movement disorders.Handb Clin Neurol. 2010;95:501-46. doi: 10.1016/S0072-9752(08)02133-7. Handb Clin Neurol. 2010. PMID: 19892136 Review.
Cited by
-
Neurosurgical management of non-spastic movement disorders.Childs Nerv Syst. 2023 Oct;39(10):2887-2898. doi: 10.1007/s00381-023-06100-1. Epub 2023 Jul 31. Childs Nerv Syst. 2023. PMID: 37522933 Free PMC article. Review.
-
Dopamine receptor and Gα(olf) expression in DYT1 dystonia mouse models during postnatal development.PLoS One. 2015 Apr 10;10(4):e0123104. doi: 10.1371/journal.pone.0123104. eCollection 2015. PLoS One. 2015. PMID: 25860259 Free PMC article.
-
Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study.Neuropsychiatr Dis Treat. 2018 Apr 26;14:1119-1124. doi: 10.2147/NDT.S152252. eCollection 2018. Neuropsychiatr Dis Treat. 2018. PMID: 29731634 Free PMC article.
-
KinesioTaping after botulinum toxin type A for cervical dystonia in adult patients.Brain Behav. 2022 Apr;12(4):e2541. doi: 10.1002/brb3.2541. Epub 2022 Mar 3. Brain Behav. 2022. PMID: 35238494 Free PMC article. Clinical Trial.
References
LinkOut - more resources
Full Text Sources